# OLIGOMA: HCP commentary report

> 238 verified statements (104 from clinicians verified by NPI or staff page) from 24 commentary sources · 11 findings · updated Oct 28, 2026

## Report

- Trial: Effectiveness and Tolerability of Metastases-directed Radiotherapy in Addition to Standard Systemic Therapy in Patients With Oligometastatic Breast Cancer: A Randomized Controlled Multinational and Multicenter Clinical Trial
- NCT ID: NCT04495309
- Registry: https://clinicaltrials.gov/study/NCT04495309
- Sponsor: University Hospital Schleswig-Holstein
- Phase: Not applicable
- Status: Completed
- Indications: Breast cancer
- Version: v1.0.0, edition 1
- Accepted: 2026-10-28
- Last checked: 2026-10-28
- Release hash: a6cef63dfa2fc12476779e29dd691945c1ea4028fec0cade6d60c79618ae2ceb

## Counts

- HCP commentary sources screened: 33
- Sources cited by verified statements: 25
- Verified statements: 238
- From speakers with a confirmed clinical role (verified by the NPI registry or their own institution's staff page): 104
- Findings: 11
- People found in screened sources: 44
- People identity-verified: 41
- Voices cited: 42
- Organisational or shared accounts (not counted as people): 3

Counts describe the retained sources. They do not estimate how many HCPs hold a view.

## Abstract

OLIGOMA asks whether adding radiotherapy to systemic therapy can delay progression without worsening quality of life in oligometastatic breast cancer. Clinicians in the sources reviewed for this edition differ over routine local treatment versus trial-only care. Enthusiasm for progression delay coexists with scrutiny of patient selection and evidence thresholds. The clinical role of SBRT and requirements for further confirmation remain unresolved.

## Open Medical Affairs question

Which patients, if any, should be considered for SBRT now, and what additional evidence would change that threshold?

Raised by the leading finding. The report shows what clinicians said and the sources behind it; it does not settle the question.

## Findings (titles)

- F1. Routine use versus trial-only care remains the consequential divide
- F2. Selection and earlier consolidation are proposed, not demonstrated, effect modifiers
- F3. BR002 population and PET explanations were corrected or left open
- F4. Biomarker enthusiasm is exploratory and contested
- F5. Systemic effectiveness and changing disease pace qualify the local-treatment question
- F6. Local-event definitions matter, but better local control would not automatically yield PFS benefit
- F7. Radioresistance remains a disputed hypothesis
- F8. The evidence dispute concerns inference, replication and cross-histology borrowing
- F9. Progression delay, quality of life and rare cure are different objectives
- F10. Equipoise and communication constrain evidence generation
- F11. Guideline omission has a timing explanation, not a proven dismissal

## What sits behind each finding

Counts describe what the report retained, not how many clinicians hold a view. A statement can support more than one finding.

| Finding | Statements | Passages | Sources | Named voices | Counterview | Limitations |
| --- | ---: | ---: | ---: | ---: | --- | ---: |
| F1 | 12 | 10 | 8 | 8 | recorded | 2 |
| F2 | 24 | 26 | 6 | 10 | recorded | 3 |
| F3 | 30 | 27 | 6 | 8 | recorded | 3 |
| F4 | 18 | 18 | 5 | 11 | recorded | 3 |
| F5 | 17 | 15 | 4 | 5 | recorded | 3 |
| F6 | 40 | 35 | 5 | 10 | recorded | 3 |
| F7 | 20 | 22 | 1 | 7 | recorded | 3 |
| F8 | 54 | 59 | 8 | 13 | recorded | 5 |
| F9 | 13 | 10 | 8 | 6 | recorded | 3 |
| F10 | 10 | 11 | 5 | 8 | recorded | 2 |
| F11 | 12 | 13 | 2 | 6 | recorded | 2 |

### What the statements are

| Finding | Views | Questions and uncertainty | Clinical experience | Comparisons | Restated results and context | Passages supporting | Passages giving context | Sources by kind | Feeds the Medical Affairs question |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | --- | --- |
| F1 | 8 | 1 | 0 | 1 | 2 | 12 | 0 | 8 posts and articles | yes |
| F2 | 12 | 3 | 0 | 4 | 5 | 25 | 3 | 4 posts and articles, 1 podcast or video, 1 publication | yes |
| F3 | 12 | 6 | 1 | 4 | 7 | 33 | 2 | 6 posts and articles | yes |
| F4 | 13 | 1 | 0 | 0 | 4 | 18 | 2 | 5 posts and articles | yes |
| F5 | 13 | 1 | 2 | 0 | 1 | 23 | 1 | 3 posts and articles, 1 podcast or video | yes |
| F6 | 12 | 12 | 0 | 11 | 5 | 40 | 1 | 4 posts and articles, 1 publication | yes |
| F7 | 12 | 6 | 1 | 1 | 0 | 22 | 2 | 1 post or article | yes |
| F8 | 37 | 6 | 1 | 6 | 4 | 57 | 4 | 6 posts and articles, 1 podcast or video, 1 publication | yes |
| F9 | 9 | 1 | 0 | 0 | 3 | 14 | 0 | 7 posts and articles, 1 publication | yes |
| F10 | 4 | 0 | 4 | 0 | 2 | 11 | 1 | 4 posts and articles, 1 publication | yes |
| F11 | 8 | 3 | 0 | 1 | 0 | 13 | 1 | 2 posts and articles | yes |

### Trial dimensions

- Primary endpoint: First co-primary outcome measure is progression-free survival (PFS): F1 (6 shared claims), F2 (2 shared claims), F6 (3 shared claims), F8 (3 shared claims), F9 (3 shared claims), F10 (1 shared claims)
- Primary endpoint: Second co-primary outcome measure is quality of life: F9 (2 shared claims)
- Secondary endpoints: F5 (1 shared claims), F7 (1 shared claims), F9 (4 shared claims)
- Population and setting: F1 (1 shared claims), F2 (14 shared claims), F3 (1 shared claims)
- The comparison: F1 (5 shared claims), F2 (3 shared claims), F5 (3 shared claims), F8 (1 shared claims), F9 (2 shared claims), F11 (1 shared claims)
- Safety and tolerability: F1 (1 shared claims), F3 (1 shared claims), F5 (2 shared claims), F8 (1 shared claims), F9 (2 shared claims)
- Design and conduct: F1 (4 shared claims), F2 (2 shared claims), F6 (2 shared claims), F10 (7 shared claims)

## Sample findings

Paraphrased; the full report links each statement to its source.

### F2. Selection and earlier consolidation are proposed, not demonstrated, effect modifiers

A Bluesky contributor asked which breast cancer subtypes were represented among OLIGOMA participants.

Source: Bluesky thread, 2026-05-17.

### F6. Local-event definitions matter, but better local control would not automatically yield PFS benefit

An X-thread contributor asked how to explain the differences between BR002 and OLIGOMA.

The discussion includes posts dated 11 and 21 October 2026; the date of this individual question is not specified.

Source: X thread.

## What's inside

| Section | Items | Access |
| --- | ---: | --- |
| Findings with interpretation, counterviews and limits | 11 | Titles free |
| Detailed analysis | 12 sections | Paid |
| Verified statements with short source quotes and links | 238 | Paid |
| Trial aspects mapped | 15 | Free |
| Sources with links | 25 | Counts free |
| Speaker attribution for cited voices | 42 | Paid |

## Trial aspects

15 discussed · 0 no commentary found · 0 assessment incomplete.

| Aspect | Coverage | Statements | Sources |
| --- | --- | ---: | ---: |
| Primary endpoint: First co-primary outcome measure is progression-free survival (PFS) | discussed | 15 | 12 |
| Primary endpoint: Second co-primary outcome measure is quality of life | discussed | 2 | 2 |
| Secondary endpoints | discussed | 4 | 3 |
| Population and setting | discussed | 16 | 6 |
| The comparison | discussed | 12 | 7 |
| Safety and tolerability | discussed | 6 | 6 |
| Design and conduct | discussed | 12 | 6 |
| Initial versus induced oligometastases and evolving BR002 interpretations | discussed | 23 | 5 |
| Imaging sensitivity, eligibility and German PET access | discussed | 7 | 3 |
| CTC and ctDNA selection: predictive hypotheses versus subgroup skepticism | discussed | 17 | 5 |
| Treated-area progression, dose and cross-study local-control comparisons | discussed | 34 | 4 |
| Radiation response, pathological viability and clinical failure | discussed | 20 | 1 |
| Evidence thresholds, replication and histology-aware pooling | discussed | 55 | 8 |
| Systemic control, longitudinal disease pace and repeat SABR | discussed | 22 | 4 |
| Guideline timing, interpretation and specialty involvement | discussed | 12 | 2 |

An aspect marked incomplete is a question the public commentary did not let us answer. We show it rather than hide it.

## Sources

| Channel | Screened | Cited |
| --- | ---: | ---: |
| X threads | 27 | 22 |
| Bluesky threads | 5 | 1 |
| YouTube | 1 | 1 |
| Publications (primary source, cited for context) | not screened | 1 |

- Screened window: 2021-04-10 to 2026-10-27
- Cited window: 2021-04-10 to 2026-10-21
- Retrieved: 2026-10-28

Screened sources were retrieved for this trial. Cited sources back at least one verified statement and include primary sources used for context.

## The trial

From ClinicalTrials.gov.

- Title: Effectiveness and Tolerability of Metastases-directed Radiotherapy in Addition to Standard Systemic Therapy in Patients With Oligometastatic Breast Cancer: A Randomized Controlled Multinational and Multicenter Clinical Trial
- Registry: NCT04495309 (https://clinicaltrials.gov/study/NCT04495309)
- Study IDs: ARO-2015-1
- Sponsor: University Hospital Schleswig-Holstein
- Design: Not applicable · interventional, randomized, parallel, na
- Status: Completed
- Enrollment: 87 (actual)
- Start: 2021-03-05 (actual)
- Primary completion: 2025-06-03 (actual)
- Primary endpoint: First co-primary outcome measure is progression-free survival (PFS) (at least 12 months after randomization)
- Primary endpoint: Second co-primary outcome measure is quality of life (12 weeks after randomization)
- Intervention: Metastases-directed Radiotherapy (radiation)

## Scope and limits

This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.

- Discussion that does not name the trial may be missing from this edition.
- The source search did not run to completion, so some matching discussion may be missing.
- 1 matching source (1 X thread) could not be read and is not included.
- Not yet captured in this edition: a view on disease differences and imaging limitations when interpreting metastasis-directed therapy evidence across cancers.
- Not yet captured in this edition: a view on investigating and quantifying potential survival or cure benefits of metastases-directed treatment.
- Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.
- 35 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.
- Further source limits: discussion that describes the trial without naming it may be incomplete; some discussion that describes the trial without naming it may be missing; sources about other trials are not included.
- Public posts and one historical interview do not establish how widely any position is shared. Reposts and repeated quotations are not additional independent opinions.
- The reviewed OLIGOMA outcomes discussion is conference-based. No primary outcomes publication is available here, and comments differ slightly in reported medians and confidence-limit rounding. These differences should not be silently combined into one verified results account.
- Speakers describe a small study stopped early for slow recruitment and a largely low-burden, earlier-line population. Enthusiasm should not be generalized to every patient eligible under the broader protocol.
- Short-term quality-of-life reports and general confidence in oligoSBRT safety do not establish formal quality-of-life non-inferiority, comprehensive graded toxicity, late effects or patient-satisfaction outcomes.
- The comments do not independently settle BR002's disputed initial-burden interpretation, characterize all treated-area events, or validate CTC/ctDNA selection thresholds. These remain open questions rather than established explanations for trial differences.
- A follow-up qualification in the survival-or-cure discussion was not available in full, limiting completeness of that exchange.
- Several contributors' clinical roles are not established in the reviewed material, and account-level or organizational commentary cannot be assumed to represent an identifiable individual clinician.

How reports are built and checked: https://www.erudio.com/methods

## Editions and corrections

- v1.0.0, accepted 2026-10-28: current edition

Last checked for new commentary 2026-10-28. No corrections. Versions follow semver: a new or changed finding is a minor version, more evidence without a material change is a patch.

## Offer

- Size: Standard (238 verified statements)
- Current edition: $1,250. A purchase starts a check for new commentary and any newer edition follows at no charge
- 3 months of weekly updates: $2,200
- 6 months of weekly updates: $3,100
- 12 months of weekly updates: $4,400
- Optional identity linkages (12-month updates only, product updates-12-identities; speakers are named and described in every report): NPI and other verified IDs at $15 per identity-verified person in the edition at purchase (41 now), at most $1,250; people verified later in the term at no charge
- Pricing: https://www.erudio.com/pricing
- Buy now (card, through Stripe): https://www.erudio.com/reports/oligoma-nct04495309
- Agents: POST https://www.erudio.com/api/orders with {"report": "oligoma-nct04495309", "product": "edition" | "updates-3" | "updates-6" | "updates-12" | "updates-12-identities", "buyer_email": "...", "licence_key": "<your key, if you hold one>"}; it returns a payment link for your user (and a pay_url your own MPP or x402 payment client can pay over HTTP 402, when offered), and once paid the status_url returns your license key. Send the same key with every later order so all reports sit on one key. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST https://www.erudio.com/api/keys/recover) sends it again
- Talk to Audun Utengen and Tom Lee (invoice, PO, questions): https://www.erudio.com/contact?report=oligoma-04495309

## Cite

Erudio Health. OLIGOMA (NCT04495309): HCP commentary report. Edition 1, v1.0.0. Accepted Oct 28, 2026. https://www.erudio.com/reports/oligoma-nct04495309

## Machine access

- JSON: https://www.erudio.com/reports/oligoma-nct04495309.json
- Markdown: https://www.erudio.com/reports/oligoma-nct04495309.md
- MCP, no sign-in: https://mcp.erudio.com/free, tool `get_report_card` with `{"slug": "oligoma-04495309"}`